Artera’s Multimodal Artificial Intelligence Named Among TIME's 2024 Best Inventions

The prestigious recognition highlights Artera’s innovation and impact in advancing the personalization of prostate cancer treatment

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced that its MMAI platform has been named among TIME’s Best Inventions of 2024 in the medical care category. Each year, TIME honors 200 groundbreaking inventions that are making the world a better place. Submissions from around the globe are rigorously evaluated, with winners selected based on originality, efficacy, ambition, and impact.

Artera’s inclusion in TIME’s prestigious list recognizes how its MMAI platform promises to transform how patients and providers personalize cancer care. The platform powers Artera’s flagship product, the ArteraAI Prostate Test, which is the first of its kind, able to both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer.

“Patients are often over-treated across all cancers, and studies show intermediate-risk localized prostate cancer is often treated suboptimally,” said Andre Esteva, founder and CEO of Artera. “Our model can offer a powerful solution, providing actionable insights to empower shared decision-making in order to personalize treatment plans. We are honored by TIME’s recognition, which highlights the tangible impact this technology is making on patient care today and the promise our platform holds for transforming cancer treatment and other healthcare fields in the future.”

Multiple factors contributed to MMAI’s selection by TIME. First, the platform is grounded in extensive research and rigorous validation, including the use of many Phase 3 randomized trials. Data supporting the platform’s efficacy has been published in leading journals, such as NEJM Evidence, and Nature. The MMAI algorithm is recommended by the National Comprehensive Cancer Network (NCCN) guidelines, which is trusted by clinicians worldwide for cancer care management and treatment. The ArteraAI Prostate Test also received a payment rate from the Centers for Medicare and Medicaid Services (CMS) earlier this year, making it more accessible to a broader patient population.

Artera’s recognition from TIME also follows a more recent milestone- the expansion of the ArteraAI Prostate Test into California after Artera received its California laboratory license from the California Department of Public Health (CDPH).

See the full TIME Best Inventions 2024 list here: time.com/best-inventions-2024

About Artera

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test.

Artera’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials.

Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera’s laboratory in Jacksonville, Florida, and can be ordered online at Artera.ai.